Metabolic (50 companies · 43 conditions)

Conditions

Obesity 10 Type 1 Diabetes 9 MASH 7 Type 2 Diabetes 7 Prader-Willi Syndrome 5 Rare Phenylketonuria 4 Rare Gout 3 Pompe Disease 3 Rare Adrenal Insufficiency 2 Bardet-Biedl Syndrome 2 Rare Classical Homocystinuria 2 Rare Congenital Adrenal Hyperplasia 2 Rare Cushing's Syndrome 2 Rare Gaucher Disease 2 Rare Glycogen Storage Disease Type Ia 2 Rare Hypoparathyroidism 2 Rare Urea Cycle Disorders 2 Rare Achondroplasia 1 Rare Acromegaly 1 Rare Aging-Related Frailty 1 Choline Deficiency 1 Congenital Hyperinsulinism 1 Rare Fabry Disease 1 Rare Hyperammonemia 1 Rare Hypothyroidism 1 Lipodystrophy 1 Rare Long-Chain Fatty Acid Oxidation Disorders 1 Rare Menkes Disease 1 Rare Mitochondrial Disease 1 Rare MPS I 1 Rare Mucopolysaccharidosis Type IIIB 1 Rare Mucopolysaccharidosis Type VII 1 Rare Neonatal Diabetes Mellitus 1 Rare Osteogenesis Imperfecta 1 Rare Osteoporosis 1 Post-Bariatric Hypoglycemia 1 Rare Sanfilippo Syndrome 1 Rare Severe Hypoglycemia 1 Severe Primary IGF-1 Deficiency 1 Rare Tumor-Induced Osteomalacia 1 Rare Tyrosinemia Type 1 1 Rare Wolfram Syndrome 1 Rare X-Linked Hypophosphatemia 1 Rare

Companies

Ticker	Company	Therapeutic areas	In Metabolic	Lead stage	Mkt cap	Programs
AARD	Aardvark Therapeutics	DermatologyMetabolic+1 Rare	1	Phase 3	$25.6M	3
AGIO	Agios Pharmaceuticals	HematologyMetabolic Rare	1	Approved	$1.76B	7
ALT	Altimmune	GI/HepatologyMetabolic+1	1	Phase 3	$405M	3
AMLX	Amylyx Pharmaceuticals	MetabolicNeurology Rare	4	Phase 3	$3.79B	5
BEAM	Beam Therapeutics	HematologyMetabolic+1 Rare	2	Phase 2	$2.73B	6
BLTE	Belite Bio	MetabolicOphthalmology Rare	4	NDA Submitted	$6.21B	6
BMEA	Biomea Fusion	MetabolicOncology	3	Phase 2	$41.1M	4
IPSC	Century Therapeutics	ImmunologyMetabolic+1 Rare	1	Phase 1	$304M	9
CMMB	Chemomab Therapeutics	GI/HepatologyImmunology+1 Rare	1	Phase 2	$10.6M	4
CRNX	Crinetics Pharmaceuticals	MetabolicOncology Rare	4	Approved	—	6
DYN	Dyne Therapeutics	MetabolicNeurology Rare	1	NDA Submitted	$3.39B	10
ELDN	Eledon Pharmaceuticals	ImmunologyMetabolic+1 Rare	1	Phase 2	$212M	3
ENTX	Entera Bio	GI/HepatologyMetabolic Rare	3	Phase 2	$547M	4
ETON	Eton Pharmaceuticals	GI/HepatologyInfectious Disease+3 Rare	8	Approved	$1.63B	17
FBIO	Fortress Biotech	DermatologyHematology+3 Rare	3	Approved	$61.7M	12
GUTS	Fractyl Health	Metabolic	1	Phase 3	—	1
GANX	Gain Therapeutics	MetabolicNeurology Rare	1	Phase 1	$45.0M	5
HRMY	Harmony Biosciences	MetabolicNeurology Rare	2	Approved	$1.94B	17
IMCR	Immunocore	DermatologyInfectious Disease+2	1	Approved	$1.60B	15
IONS	Ionis Pharmaceuticals	CardiovascularHematology+5 Rare	1	Approved	$6.55B	29
KURA	Kura Oncology	MetabolicOncology	2	Approved	$647M	12
LCTX	Lineage Cell Therapeutics	MetabolicNeurology+1 Rare	1	Phase 2	$258M	12
LGVN	Longeveron	CardiovascularMetabolic+1 Rare	1	Phase 2	$5.8M	4
MAZE	Maze Therapeutics	MetabolicRenal Rare	2	Phase 2	$1.90B	4
MGTX	MeiraGTx	ImmunologyMetabolic+2 Rare	3	Phase 3	$864M	16
GLUE	Monte Rosa Therapeutics	CardiovascularDermatology+3 Rare	1	Phase 2	$903M	7
NKTR	Nektar Therapeutics	DermatologyImmunology+2	1	Phase 3	$1.27B	11
NAMS	NewAmsterdam Pharma	CardiovascularMetabolic+1	1	NDA Submitted	$2.27B	6
PTN	Palatin Technologies	ImmunologyMetabolic+1 Rare	4	Phase 3	$11.2M	8
DTIL	Precision Biosciences	Infectious DiseaseMetabolic+1 Rare	2	Phase 1	$296M	5
PRQR	ProQR Therapeutics	MetabolicNeurology Rare	2	Phase 1	$191M	7
PTGX	Protagonist Therapeutics	DermatologyHematology+2 Rare	3	Approved	$8.62B	12
TARA	Protara Therapeutics	DermatologyMetabolic+1 Rare	1	Phase 3	$142M	3
RLMD	Relmada Therapeutics	MetabolicNeurology+1 Rare	1	Phase 2	$416M	4
RYTM	Rhythm Pharmaceuticals	Metabolic Rare	14	Approved	$7.78B	14
SABS	SAB Biotherapeutics	Metabolic	1	Phase 2	$273M	1
SGMT	Sagimet Biosciences	DermatologyMetabolic	1	Phase 3	$698M	3
SANA	Sana Biotechnology	MetabolicOncology	2	Phase 1	$710M	4
SEPN	Septerna	ImmunologyMetabolic+1 Rare	1	Phase 1	$2.28B	5
SPRB	Spruce Biosciences	Metabolic Rare	2	Preclinical	$134M	2
GPCR	Structure Therapeutics	MetabolicRespiratory Rare	4	Phase 3	$4.35B	5
TVTX	Travere Therapeutics	MetabolicRenal Rare	1	Approved	$4.76B	7
TYRA	Tyra Biosciences	MetabolicOncology Rare	1	Phase 2	$1.26B	5
RARE	Ultragenyx Pharmaceutical	CardiovascularMetabolic+1 Rare	8	Approved	$1.57B	10
QURE	uniQure	HematologyMetabolic+1 Rare	1	Approved	$1.52B	4
VKTX	Viking Therapeutics	MetabolicNeurology Rare	6	Phase 3	$3.42B	9
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	1	Phase 1	$116M	9
VTVT	vTv Therapeutics	HematologyMetabolic+1 Rare	4	Phase 3	$84.4M	9
WVE	Wave Life Sciences	MetabolicNeurology+1 Rare	2	Phase 2	$665M	5
XERS	Xeris Biopharma	MetabolicNeurology Rare	3	Approved	$2.78B	4